ALEMBICLTD
PharmaceuticalsAlembic Ltd
Alembic Ltd. is a pharmaceutical company based in India, founded in 1907. The company produces a wide range of pharmaceutical products, including active pharmaceutical ingredients, generic drugs, and branded generic drugs. Alembic operates in the domestic and international markets, with a strong presence in the Indian market and a growing presence in international markets such as the US, Europe, and the Middle East.
In terms of financial performance, Alembic has shown strong growth in recent years, driven by increasing demand for its products both domestically and internationally. The company's revenue and profit margins have been consistently increasing, reflecting its ability to capture growth opportunities in the pharmaceuticals industry.
Alembic's primary competitors in the pharmaceuticals industry include other Indian pharmaceutical companies as well as multinational pharmaceutical companies operating in the Indian market. The pharmaceuticals industry in India is highly competitive, with many established players and a growing number of new entrants.
Strong brand recognition and reputation for quality products
Diverse product portfolio with a focus on high-growth segments of the pharmaceuticals industry
Strong distribution network in India and growing presence in international markets
- Trades at a P/E of 13.5, with a return on equity (ROE) of 12.6%.
- ALEMBICLTD is trading above 4 of 5 of its key moving averages (10/20/50/100/200-DMA) — a bullish technical setup.
- Year-to-date it is up 5.55%, and up 5.08% over the past year.
- At ₹104.33 it sits about 72% of the way up its 52-week range (₹70.46–₹117.72).
- Offers a dividend yield of 1.7%.
- Market capitalisation stands at ₹2,683 Cr.
Shareholding data syncs daily.
| Year | Revenue | Net Profit | EPS | NPM |
|---|---|---|---|---|
| Mar 2023 | ₹123 Cr | ₹79 Cr | ₹3.09 | 64.23% |
| Mar 2022 | ₹78 Cr | ₹222 Cr | ₹8.65 | 284.62% |
| Mar 2021 | ₹74 Cr | ₹343 Cr | ₹13.35 | 463.51% |
| Mar 2021 | ₹74 Cr | ₹343 Cr | ₹13.35 | 463.51% |
| Mar 2020 | ₹74 Cr | ₹329 Cr | ₹12.82 | 444.59% |
| Mar 2020 | ₹74 Cr | ₹329 Cr | ₹12.82 | 444.59% |
| Mar 2019 | ₹124 Cr | ₹213 Cr | ₹8.30 | 171.77% |
| Mar 2019 | ₹124 Cr | ₹213 Cr | ₹8.30 | 171.77% |
| Mar 2018 | ₹125 Cr | ₹163 Cr | ₹6.10 | 130.4% |
| Mar 2017 | ₹147 Cr | ₹145 Cr | ₹5.44 | 98.64% |
| Mar 2016 | ₹134 Cr | ₹235 Cr | ₹8.75 | 175.37% |
| Mar 2015 | ₹144 Cr | ₹107 Cr | ₹3.96 | 74.31% |
| Company | P/E | Book Value | Sales Growth |
|---|---|---|---|
| SUNPHARMA SUN PHARMACEUTICAL INDUSTRIES LTD. | 39.1 | ₹98.33 | 10.1% |
| MARKSANS MARKSANS PHARMA LTD. | 23.8 | ₹11.85 | 5.8% |
| MOREPENLAB MOREPEN LABORATORIES LTD. | 20.81 | ₹6.43 | 16.6% |
| NEULANDLAB NEULAND LABORATORIES LTD. | 23.48 | ₹542.16 | 9.35% |
| GUFICBIO Gufic BioSciences Ltd. | 24.16 | ₹10.85 | 20.41% |
| DIVISLAB DIVI'S LABORATORIES LTD. | 41.01 | ₹266.77 | 9.47% |
| DRREDDY DR.REDDY'S LABORATORIES LTD. | 19.73 | ₹852.69 | 1.07% |
| RPGLIFE RPG LIFE SCIENCES LTD. | 17.14 | ₹105.02 | 5.73% |
| GLAND Gland Pharma Ltd | 53.6 | ₹242.00 | — |
| ZYDUSLIFE Zydus Lifesciences Ltd | 8.23 | ₹166.00 | 5% |
| SMSPHARMA SMS PHARMACEUTICALS LTD. | 9.58 | ₹42.07 | -8.73% |
| CIPLA CIPLA LTD. | 15.36 | ₹209.71 | 0.7% |
| Date | Client | Type | Qty | Price |
|---|---|---|---|---|
| 05 Jun 2020 | NIRAYU PRIVATE LIMITED | PURCHASE | 18,91,394 | ₹54.00 |
| 17 Jun 2019 | NIRAYU PRIVATE LIMITED | PURCHASE | 24,85,844 | ₹40.60 |
| 17 Jun 2019 | UDAY EDUCATION SOCIETY | SALE | 19,48,201 | ₹40.50 |
| 29 Feb 2012 | PAT FINANCIAL CONSULTANT PVT LTD | PURCHASE | 10,80,546 | ₹16.60 |
| 16 Aug 2007 | FIDELITY INDIAN MUTUAL FUND AC FIDELITY EQUITY FUND | PURCHASE | 10,61,485 | ₹72.50 |
| 16 Aug 2007 | MORGAN STANLEY AND CO INTL AC MORGAN STANLEY DEAN WITTER MAU LTD | SALE | 20,75,000 | ₹72.50 |
| 14 Aug 2007 | FIDELITY INDIAN MUTUAL FUND AC FIDELITY EQUITY FUND | PURCHASE | 22,77,688 | ₹74.00 |
| 14 Aug 2007 | HSBC FINANCIAL SERVICES MIDDLEEAST LIMITED | SALE | 9,57,725 | ₹74.00 |
| 14 Aug 2007 | MACQUARIE BANK LIMITED | SALE | 20,82,500 | ₹74.00 |
| 15 Sept 2006 | ARISAIG PARTNERS ASIA PTE | SALE | 2,47,000 | ₹368.00 |
| 07 Jun 2006 | MACQUARIE BANK LIMITED | PURCHASE | 4,18,000 | ₹307.00 |
| 07 Jun 2006 | THE MASTER TRUST BANK OF | SALE | 4,17,550 | ₹307.00 |
Fundamentals, financials & technicals sourced from niftytrader.in, cached and refreshed periodically.